公开(公告)号：US11407757B2

公开(公告)日：2022-08-09

申请号：US16958721

申请日：2018-12-26

Applicant: Development Center for Biotechnology

Inventor： Shih-Chieh Yen ,  Chu-Bin Liao ,  Hui-Chen Wang ,  Po-Ting Chen ,  Yu-Chih Pan ,  Tsung-Hui Li ,  Bo-Rong Chen ,  Shian-Yi Chiou

IPC: C07D487/04 ,  A61P35/00

Abstract: Disclosed are compounds of formula (I) below and tautomers, stereoisomers, isotopologues, or pharmaceutically acceptable salts thereof: in which each of variables R1, ring A, L, W, V, and G is defined herein. Also disclosed are a method for treating disease or disorder mediated by Tyro3, Axl, and/or Mer kinase with a compound of formula (I) or a tautomer, stereoisomer, isotopologue, or salt thereof and a pharmaceutical composition containing same.

公开(公告)号：US10689362B2

公开(公告)日：2020-06-23

申请号：US16340685

申请日：2017-10-09

Applicant: Development Center for Biotechnology

Inventor： Shao-Zheng Peng ,  Chu-Bin Liao ,  Hung-Kai Chen ,  Chen-Hsuan Ho ,  Hung-Jyun Huang ,  Shian-Yi Chiou

IPC: A61K31/44 ,  A61K31/498 ,  A61P35/00 ,  C07D241/40 ,  C07D241/44 ,  C07D401/06 ,  C07D401/12 ,  C07D241/52 ,  C07D401/14 ,  C07D413/04 ,  C07D413/14 ,  C07D401/04 ,  C07D413/12 ,  C07D403/04 ,  C07D405/12 ,  C07D409/12 ,  C07D403/12 ,  C07D403/14

Abstract: A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can be used in the treatments of diseases or conditions mediated by CSF-1R, c-KIT, FLT3, or PDGFR kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.

公开(公告)号：US20190308949A1

公开(公告)日：2019-10-10

申请号：US16340685

申请日：2017-10-09

Applicant: Development Center for Biotechnology

Inventor： Shao-Zheng Peng ,  Chu-Bin Liao ,  Hung-Kai Chen ,  Chen-Hsuan Ho ,  Hung-Jyun Huang ,  Shian-Yi Chiou

IPC: C07D401/12 ,  C07D401/14 ,  C07D241/52 ,  C07D413/04 ,  C07D413/14 ,  A61P35/00

Abstract: A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can be used in the treatments of diseases or conditions mediated by CSF-1R, c-KIT, FLT3, or PDGFR kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.